These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7656018)

  • 1. Metalloproteinase superfamilies and drug design.
    Blundell TL
    Nat Struct Biol; 1994 Feb; 1(2):73-5. PubMed ID: 7656018
    [No Abstract]   [Full Text] [Related]  

  • 2. The molecular and cellular interactions involved in connective tissue destruction.
    Reynolds JJ
    Br J Dermatol; 1985 Jun; 112(6):715-23. PubMed ID: 3890925
    [No Abstract]   [Full Text] [Related]  

  • 3. The connective tissue connection.
    Nat Struct Biol; 1994 Feb; 1(2):71-2. PubMed ID: 7656017
    [No Abstract]   [Full Text] [Related]  

  • 4. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases.
    Docherty AJ; O'Connell J; Crabbe T; Angal S; Murphy G
    Trends Biotechnol; 1992 Jun; 10(6):200-7. PubMed ID: 1368394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases.
    Fragai M; Nativi C; Richichi B; Venturi C
    Chembiochem; 2005 Aug; 6(8):1345-9. PubMed ID: 15977273
    [No Abstract]   [Full Text] [Related]  

  • 6. Metalloproteinases and tissue damage.
    Murphy G; Docherty AJ; Hembry RM; Reynolds JJ
    Br J Rheumatol; 1991; 30 Suppl 1():25-31. PubMed ID: 1991237
    [No Abstract]   [Full Text] [Related]  

  • 7. The regulation of connective tissue metalloproteinases by natural inhibitors.
    Murphy G
    Agents Actions Suppl; 1991; 35():69-76. PubMed ID: 1781423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
    Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peculiarities of tissue enzyme patterns in connective tissue proliferation and their possible diagnostic significance].
    Fischer W; Werner G; Grund E
    Radiobiol Radiother (Berl); 1983; 24(3):335-43. PubMed ID: 6635164
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthetic considerations of matrix metalloproteinase inhibitors.
    Skotnicki JS; Zask A; Nelson FC; Albright JD; Levin JI
    Ann N Y Acad Sci; 1999 Jun; 878():61-72. PubMed ID: 10415720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints.
    Takagi M; Santavirta S; Ida H; Ishii M; Mandelin J; Konttinen YT
    Clin Orthop Relat Res; 1998 Jul; (352):35-45. PubMed ID: 9678031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing inhibitors of the metalloproteinase superfamily: comparative analysis of representative structures.
    Dhanaraj V; Ye QZ; Johnson LL; Hupe DJ; Ortwine DF; Dunbar JB; Rubin JR; Pavlovsky A; Humblet C; Blundell TL
    Drug Des Discov; 1996 Apr; 13(3-4):3-14. PubMed ID: 8874040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases in sterile corneal melts.
    Geerling G; Joussen AM; Daniels JT; Mulholland B; Khaw PT; Dart JK
    Ann N Y Acad Sci; 1999 Jun; 878():571-4. PubMed ID: 10415776
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioactive conformation of stromelysin inhibitors determined by transferred nuclear Overhauser effects.
    Gonnella NC; Bohacek R; Zhang X; Kolossváry I; Paris CG; Melton R; Winter C; Hu SI; Ganu V
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):462-6. PubMed ID: 7831311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of plasminogen activators in the regulation of connective tissue metalloproteinases.
    Murphy G; Atkinson S; Ward R; Gavrilovic J; Reynolds JJ
    Ann N Y Acad Sci; 1992 Dec; 667():1-12. PubMed ID: 1339240
    [No Abstract]   [Full Text] [Related]  

  • 18. Role and regulation of metalloproteinases in connective tissue turnover.
    Murphy G; Hembry RM; Hughes CE; Fosang AJ; Hardingham TE
    Biochem Soc Trans; 1990 Oct; 18(5):812-5. PubMed ID: 2083684
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and identification of conformationally constrained selective MMP inhibitors.
    Freskos JN; McDonald JJ; Mischke BV; Mullins PB; Shieh HS; Stegeman RA; Stevens AM
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1757-60. PubMed ID: 10406637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor.
    Smith AB; Nittoli T; Sprengeler PA; Duan JJ; Liu RQ; Hirschmann RF
    Org Lett; 2000 Nov; 2(24):3809-12. PubMed ID: 11101425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.